Put Concerns About Ranitidine and Drug Safety in Perspective

November 2019

Headlines about a probable carcinogen in some Rx and OTC ranitidine products will raise questions about the safety of generic and brand meds.

The buzz is about N-nitrosodimethylamine (NDMA)...the impurity that first sparked recalls of irbesartan, losartan, and valsartan.

Now Health Canada is investigating how much NDMA is in ranitidine...whether it poses any risk...and the source.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Med Safety Put Concerns About Ranitidine and Drug Safety in Perspective
Pain Management Clarify How to Treat Acute Pain in Patients on Buprenorphine/Naloxone
Hyperkalemia Consider New Options When a Potassium Binder Is Needed for Chronic Hyperkalemia
Heart Failure Don't Jump to an SGLT2 Inhibitor for Heart Failure
HIV & AIDS Be Prepared to Discuss Dovato, a New Two-Med Combo for HIV
Breast Cancer Weigh Pros and Cons of Meds for Primary Prevention of Breast Cancer
Diabetes & Endocrinology Watch for Signs of Pancreatitis in Patients Taking Methimazole
Alcohol Be Ready to Answer the Question, "Is It Okay to Drink Alcohol With This Med?"
HIV & AIDS Know How Descovy and Truvada Stack Up for HIV Pre-Exposure Prophylaxis (PrEP)
Dermatology Set Realistic Expectations for Patients Asking About Scar Treatments